Dexcom made a significant design change to a component used in its sensors and did not adequately validate the change, ...
Zacks Investment Research on MSN3d
DXCM Stock Falls as FDA Warnings Raise Concern for 15-Day G7 ApprovalDexCom DXCM is facing regulatory scrutiny following a warning letter recently posted by the FDA. This could affect the ...
The general mood among these heavyweight investors is divided, with 12% leaning bullish and 50% bearish. Among these notable ...
Dexcom’s investigational 15-day continuous glucose monitor has a lower mean absolute relative difference than the current ...
A company spokesperson said Dexcom plans to resolve the agency's concerns but stated no design changes were made to its ...
Sales of Beta Bionics insulin pumps spiked 145% in the fourth quarter behind solid new patient starts. Elsewhere, former ...
The agency cited quality issues at facilities testing Dexcom’s G6 and G7 monitors, including inadequate validation and risk ...
DexCom (NasdaqGS:DXCM) witnessed a 4% increase in its share price over the past week, as the company announced a significant integration of its G7 Continuous Glucose Monitoring Systems with Nanowear's ...
DexCom Inc. closed 46.96% short of its 52-week high of $142.00, which the company achieved on March 26th.
Shares of DexCom Inc. slipped 3.69% to $69.47 Thursday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index falling 0.33% to 5,693.31 and Dow Jones ...
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on NexGel Inc (NXGL – Research Report) and Dexcom ...
DexCom Inc. closed 48.20% below its 52-week high of $142.00, which the company reached on March 26th.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback